Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

IBRX ImmunityBio Inc

Price (delayed)

$2.93

Market cap

$2.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$3.35B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's revenue has surged by 112% QoQ
The company's gross profit has surged by 111% QoQ
ImmunityBio's equity has decreased by 21% QoQ but it has increased by 15% YoY
The debt has declined by 8% year-on-year but it rose by 4.3% since the previous quarter
ImmunityBio's quick ratio has decreased by 50% YoY and by 42% from the previous quarter

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
882.62M
Market cap
$2.59B
Enterprise value
$3.35B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
80.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.23
Earnings
Revenue
$31.22M
Gross profit
$31.16M
Operating income
-$313.42M
Net income
-$409.1M
EBIT
-$263.63M
EBITDA
-$240.81M
Free cash flow
-$376.91M
Per share
EPS
-$0.54
EPS diluted
-$0.58
Free cash flow per share
-$0.44
Book value per share
-$0.69
Revenue per share
$0.04
TBVPS
$0.34
Balance sheet
Total assets
$303.76M
Total liabilities
$894.24M
Debt
$822.56M
Equity
-$591.43M
Working capital
$59.96M
Liquidity
Debt to equity
-1.39
Current ratio
2.22
Quick ratio
1.61
Net debt/EBITDA
-3.16
Margins
EBITDA margin
-771.3%
Gross margin
99.8%
Net margin
-1,310.3%
Operating margin
-1,003.8%
Efficiency
Return on assets
-109.4%
Return on equity
N/A
Return on invested capital
-24%
Return on capital employed
-103.6%
Return on sales
-844.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
8.12%
1 week
19.11%
1 month
15.35%
1 year
-52.36%
YTD
14.45%
QTD
-2.66%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$31.22M
Gross profit
$31.16M
Operating income
-$313.42M
Net income
-$409.1M
Gross margin
99.8%
Net margin
-1,310.3%
ImmunityBio's revenue has surged by 112% QoQ
The company's gross profit has surged by 111% QoQ
ImmunityBio's operating margin has soared by 99% YoY and by 57% from the previous quarter
The net margin has surged by 99% year-on-year and by 53% since the previous quarter

Price vs fundamentals

How does IBRX's price correlate with its fundamentals

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
80.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.23
ImmunityBio's EPS has surged by 50% YoY and by 8% QoQ
ImmunityBio's equity has decreased by 21% QoQ but it has increased by 15% YoY
ImmunityBio's revenue has surged by 112% QoQ
The P/S is 98% less than the 5-year quarterly average of 4632.6 and 92% less than the last 4 quarters average of 968.9

Efficiency

How efficient is ImmunityBio business performance
ImmunityBio's return on sales has surged by 99% YoY and by 52% QoQ
The company's return on invested capital has surged by 56% YoY but it fell by 3.4% QoQ
IBRX's return on assets is up by 26% year-on-year but it is down by 5% since the previous quarter

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 66% less than the total liabilities
ImmunityBio's quick ratio has decreased by 50% YoY and by 42% from the previous quarter
The current ratio has decreased by 39% YoY and by 34% from the previous quarter
ImmunityBio's equity has decreased by 21% QoQ but it has increased by 15% YoY
The company's debt to equity rose by 14% QoQ but it fell by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.